What is the recommended initial management of hyperthyroidism in adults?

Initial Management of Hyperthyroidism in Adults

For adults with confirmed hyperthyroidism, initiate methimazole as first-line antithyroid drug therapy (except in first trimester pregnancy when propylthiouracil is preferred), combined with beta-blockers for immediate symptom control, while simultaneously determining the underlying etiology through TSH-receptor antibodies, thyroid ultrasound, and clinical assessment to guide definitive treatment decisions. 1, 2, 3, 4

Confirm the Diagnosis Biochemically

• Measure serum TSH, free T4 (FT4), and free T3 (FT3) to confirm hyperthyroidism—characterized by suppressed TSH with elevated FT4 and/or FT3. 5, 3, 4
• A low TSH alone is insufficient; you must document elevated thyroid hormones to distinguish true hyperthyroidism from other causes of TSH suppression. 5, 3

Determine the Underlying Etiology

• Graves' disease (70% of cases): Check TSH-receptor antibodies (TSH-R-Ab), which are positive in Graves' disease; thyroid ultrasound shows diffuse hypervascularity and hypoechogenicity; patients may have associated orbitopathy. 5, 2, 3
• Toxic nodular goiter (16% of cases): Thyroid ultrasound reveals nodules; radioiodine uptake scan shows focal or patchy increased uptake; TSH-R-Ab are typically negative. 5, 3, 4
• Destructive thyroiditis (3% of cases): Presents with low or absent radioiodine uptake on scan; often follows a biphasic course (hyperthyroid phase followed by hypothyroid phase); thyroid peroxidase antibodies may be positive in subacute thyroiditis. 1, 5, 3
• Drug-induced hyperthyroidism (9% of cases): Review medication history for amiodarone, tyrosine kinase inhibitors, immune checkpoint inhibitors, or excessive iodine exposure. 5, 3

Initiate Antithyroid Drug Therapy

• Methimazole is the preferred first-line antithyroid drug due to superior efficacy, safety profile, and once-daily dosing convenience compared to propylthiouracil. 1, 2, 3, 4
• Starting dose: 10-20 mg daily for mild hyperthyroidism; 30-40 mg daily for severe hyperthyroidism or large goiter. 1, 6
• Propylthiouracil is reserved for: (1) first trimester of pregnancy (due to lower risk of congenital malformations compared to methimazole), (2) patients intolerant to methimazole, or (3) thyroid storm. 1, 2, 3, 4
• Propylthiouracil dosing: 150-200 mg daily in divided doses (typically three times daily due to shorter half-life). 6

Monitoring Antithyroid Drug Therapy

• Monitor free T4 or free T3 every 2-4 weeks initially to guide dose adjustments; the goal is to maintain thyroid hormones in the high-normal range using the lowest effective dose. 1, 4, 6
• Do NOT use TSH to guide dose adjustments during initial treatment—TSH remains suppressed for months even after achieving euthyroidism due to prolonged pituitary suppression. 1, 6
• Common pitfall: Reducing methimazole dose based solely on suppressed TSH while free T4 remains elevated leads to inadequate treatment and recurrent hyperthyroidism. 1
• Once euthyroid (typically 4-8 weeks), reduce to maintenance dose: 5-10 mg methimazole daily or 50-100 mg propylthiouracil twice daily. 1, 6

Critical Adverse Effects Requiring Immediate Action

• Agranulocytosis (0.2-0.5% incidence): Typically occurs within first 3 months; presents with sore throat, fever, or mouth ulcers; requires immediate CBC and permanent discontinuation of antithyroid drug if confirmed. 1, 2, 3
• Hepatotoxicity: More common with propylthiouracil; monitor for fever, nausea, vomiting, right upper quadrant pain, dark urine, jaundice; discontinue drug immediately if suspected. 1, 2, 3
• Vasculitis: Rare but life-threatening; watch for skin changes, hematuria, respiratory symptoms; requires immediate drug discontinuation. 1
• Baseline and periodic monitoring: Obtain baseline CBC and liver function tests; educate patients to report symptoms immediately rather than relying on routine monitoring to detect agranulocytosis. 2, 3

Provide Immediate Symptomatic Relief with Beta-Blockers

• Beta-blockers provide rapid symptom control for tachycardia, tremor, anxiety, and heat intolerance while awaiting normalization of thyroid hormones (typically 4-8 weeks). 1, 2, 3, 4
• Preferred agents: Atenolol 25-50 mg daily (once-daily dosing, cardioselective) or propranolol 20-40 mg three to four times daily (additional benefit of blocking peripheral T4-to-T3 conversion). 1, 2, 3
• Titrate to target heart rate <90 bpm if blood pressure tolerates; higher doses may be needed in severe hyperthyroidism. 1
• Reduce beta-blocker dose once euthyroid to avoid bradycardia and hypotension, as thyroid hormone excess no longer drives tachycardia. 1, 2
• Alternative if beta-blockers contraindicated: Non-dihydropyridine calcium channel blockers (diltiazem or verapamil) for rate control. 1, 2

Special Considerations for Destructive Thyroiditis

• Antithyroid drugs are NOT indicated in destructive thyroiditis because the hyperthyroidism results from passive release of preformed thyroid hormones, not increased synthesis. 1, 5, 3, 4
• Management is supportive: Beta-blockers for symptom control during the hyperthyroid phase (typically 2-8 weeks). 1, 3
• Monitor for hypothyroid phase: Check free T4 every 2 weeks; initiate levothyroxine if patient becomes hypothyroid (low free T4/T3, even if TSH not yet elevated). 1, 3
• Corticosteroids (prednisone 40 mg daily, tapered over 4-6 weeks) are reserved for severe, painful subacute thyroiditis unresponsive to NSAIDs. 5, 3

Treatment Duration and Definitive Therapy Planning

• Standard course for Graves' disease: 12-18 months of antithyroid drug therapy, then attempt discontinuation. 2, 3, 4, 6
• Recurrence rate after 12-18 months: Approximately 50% of patients relapse within 1-2 years of stopping antithyroid drugs. 5, 2, 3
• Predictors of recurrence: Age <40 years, FT4 ≥40 pmol/L at diagnosis, TSH-binding inhibitory immunoglobulins >6 U/L, goiter size ≥WHO grade 2. 5
• Long-term antithyroid drug therapy (5-10 years) is a viable alternative with lower recurrence rates (15%) compared to short-term therapy, particularly in patients who prefer to avoid radioactive iodine or surgery. 5, 2
• Definitive therapy options after relapse: Radioactive iodine (I-131) ablation (most common in U.S.) or total thyroidectomy; choice depends on patient preference, presence of orbitopathy, goiter size, and contraindications. 2, 3, 4

Management of Subclinical Hyperthyroidism

• **TSH <0.1 mIU/L with normal FT4/FT3:** Treat patients >60 years or those with cardiac disease, osteopenia, or osteoporosis due to 3-fold increased risk of atrial fibrillation over 10 years and increased cardiovascular mortality. 1, 7, 8
• TSH 0.1-0.45 mIU/L with normal FT4/FT3: Routine treatment not recommended due to insufficient evidence of adverse outcomes; consider treatment only in elderly patients with cardiovascular risk factors. 1, 7, 8
• Treatment options for subclinical hyperthyroidism: Low-dose methimazole (5-10 mg daily) or definitive therapy (radioactive iodine or thyroidectomy) depending on etiology and patient preference. 7, 8

Pregnancy-Specific Considerations

• Switch to propylthiouracil when planning pregnancy and during first trimester due to lower risk of congenital malformations (methimazole associated with aplasia cutis and choanal/esophageal atresia). 1, 2, 3, 4
• After first trimester, switch back to methimazole due to lower risk of maternal hepatotoxicity with methimazole. 1, 2, 3
• Target FT4 in upper half of normal range using lowest possible antithyroid drug dose to minimize fetal hypothyroidism risk. 2, 3
• Both propylthiouracil and methimazole are compatible with breastfeeding at standard doses. 1, 3
• Radioactive iodine is absolutely contraindicated in pregnancy and breastfeeding; avoid pregnancy for 4-6 months after I-131 treatment. 1, 2, 3

Cardiovascular Complications Requiring Urgent Management

• Atrial fibrillation occurs in 5-15% of hyperthyroid patients, more frequently in those >60 years; beta-blockers are first-line for rate control. 1, 2, 3
• Anticoagulation decisions based on CHA₂DS₂-VASc score, not solely on presence of hyperthyroidism; many patients can discontinue anticoagulation after achieving euthyroidism if no other risk factors. 1, 2
• Cardioversion is generally unsuccessful while thyrotoxic; achieve euthyroidism first before attempting rhythm control strategies. 1, 2
• Hyperthyroidism increases cardiac output and reduces systemic vascular resistance, which can precipitate heart failure in patients with underlying cardiac disease; beta-blockers provide immediate cardiovascular protection. 1, 2

Critical Pitfalls to Avoid

• Never reduce antithyroid drug dose based on suppressed TSH alone—TSH lags behind normalization of thyroid hormones by months; use free T4/T3 to guide adjustments. 1, 6
• Do not attempt cardioversion in thyrotoxic patients—rhythm control is ineffective until euthyroid state achieved. 1, 2
• Avoid radioactive iodine in patients with active/severe Graves' orbitopathy—can worsen eye disease; use antithyroid drugs or thyroidectomy instead. 2, 3, 9
• Do not use antithyroid drugs for destructive thyroiditis—they are ineffective because hyperthyroidism results from hormone release, not increased synthesis. 1, 5, 3
• Educate patients about agranulocytosis symptoms (sore throat, fever, mouth ulcers) and instruct them to stop drug and seek immediate medical attention if these occur. 1, 2, 3